SFY0 Stock Chart & Stats
€2.42
€0.00(0.00%)
At close: 4:00 PM EDT
€2.42
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.42 - €2.42
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€8.50M
Enterprise Value€3.70M
Total Cash (Recent Filing)€11.34M
Total Debt (Recent Filing)€3.55M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 17, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,892,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.89Price Target Upside-63.23% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€25.25M
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressVIRAGE2 advances VCN-01 into a focused clinical study while building on prior survival and progression-free-survival results. The trial may refine dosing for a potential pivotal Phase 3 program, creating a clearer development path and strengthening the company’s oncology pipeline over the next several quarters.
Oncolytic Virotherapy EvidenceThe reported translational findings support a coherent mechanism in which VCN-01 may degrade tumor stroma and improve immune-cell access. Evidence across viral activity, tumor biopsies, and survival outcomes could support additional combination studies and improve the platform’s strategic appeal.
Modest LeverageModest reported leverage and still-positive equity provide more balance-sheet flexibility than a highly indebted development-stage company would have. This does not remove financing needs, but it gives Theriva some capacity to continue advancing clinical programs while managing capital allocation and funding decisions.
Bears Say
Minimal Commercial TractionTheriva has not yet demonstrated scalable commercial traction, leaving its business model dependent on clinical advancement rather than recurring product sales. The very small revenue base remains far below the cost structure, so future operating progress depends heavily on successful development and eventual commercialization.
Persistent Cash BurnOngoing operating and free-cash-flow deficits show that research and clinical execution consume substantial cash without internally funding operations. Although burn improved from 2024–2025 levels, continued negative cash generation means Theriva will likely require additional financing or other capital sources to sustain development.
Dilution And Financing OverhangThe approved capital structure changes expand the potential supply of common shares through equity awards, warrant exercises, and authorized-share capacity. That flexibility may support funding and retention, but it also creates a durable dilution risk for existing holders while losses and cash needs remain substantial.
Theriva Biologics News
SFY0 FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was €2.42 and its highest was €2.42 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is €8.50M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Nov 17, 2026 which is in 29 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Aug 11, 2026. The company reported -€0.062 earnings per share for the quarter, missing the consensus estimate of -€0.049 by -€0.013.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Overvalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.06.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,690 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -€0.062 in its last earnings report, missing expectations of -€0.049. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in DE:SFY0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
SFY0 Stock 12 Month Forecast
Average Price Target
€0.89
▼(-63.23% Downside)